Sarepta Therapeutics
@Sarepta
Followers
5,466
Following
62
Media
743
Statuses
1,002
Commercial-stage biopharma company focused on the discovery & development of precision genetic medicine to treat rare neuromuscular diseases.
Cambridge, MA
Joined November 2013
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Luka
• 338966 Tweets
ダービー
• 54409 Tweets
Kano
• 51236 Tweets
#超超超超ゲーマーズday1
• 34988 Tweets
Our Beloved TAYNEW🧸
• 29235 Tweets
サクナヒメ
• 28663 Tweets
ジャスコ
• 19806 Tweets
マイフリ
• 19784 Tweets
#MUSICFAIR
• 18835 Tweets
レイちゃん
• 16969 Tweets
아카라카
• 15843 Tweets
クマフェス
• 13919 Tweets
DOYOUNG SEOUL CONCERT DAY1
• 13498 Tweets
ビーズリー
• 13360 Tweets
葵ステークス
• 11475 Tweets
Are you attending
@CureDuchenne
FUTURES and have a question for Sarepta? Our team is available throughout the conference at our two booths and our Lego activity. Hope to see you there!
6
3
10
We’re thrilled to be a Diamond sponsor
@CureDuchenne
’s FUTURES conference on May 23-26 and look forward to connecting with families in Orlando, Florida.
0
3
19
Are you heading to
#ASGCT2024
in Baltimore? Come find our Sarepta team! We are excited to be among peers dedicated to gene and cell therapy.
0
0
6
Congratulations to Dr. Jerry Mendell on being named to the inaugural Time100 Health list! The list recognizes individuals who most influenced global health this year, and it is an acknowledgement of Dr. Mendell’s impact, innovation and achievement.
3
11
84
Today, we announced the opening of the 2024 Sarepta LGMD Grant Award Program. Open to non-governmental and patient advocacy organizations from across the globe, it aims to help shorten the LGMD diagnostic journey. Read our news release to learn more:
11
4
24
We just announced our Q4 and full-year 2023 financial results and recent corporate developments.
7
5
11
Leading up to
#RareDiseaseDay
, we’re talking about the importance of
#newbornscreening
for rare genetic diseases. We support the inclusion of Duchenne in existing
#NBS
programs so that that all patients have the chance to benefit from early diagnosis and treatment.
4
14
31
ICYMI: Earlier today, SRPT leadership shared an update on Study SRP-5051-201, MOMENTUM. Listen here:
5
2
11
Listen live: SRPT leadership shares an update on Study SRP-5051-201, MOMENTUM.
4
1
17
NEWS: Sarepta announces new positive data from Study 5051-201, MOMENTUM. Read the press release:
4
10
43
The inclusion of Duchenne on Minnesota's newborn screening panel is a significant step forward. Congratulations to the advocates who supported this cause and kudos to the Advisory Committee for recognizing the urgent need. Because when it comes to Duchenne, time is muscle.
NEWS RELEASE: MDH will add Duchenne muscular dystrophy to the list of conditions for which Minnesota newborns are routinely screened:
0
2
5
3
6
45
NEWS: Today we announced that screening is underway in Study SRP-9003-301, also known as EMERGENE, a Phase 3, multi-national, open-label study of investigational candidate SRP-9003 for the treatment of LGMD Type 2E. Read the press release:
6
11
53
We just announced our preliminary fourth quarter and full-year 2023 net product revenues. Read our press release for details:
2
1
11
We just announced our Q3 2023 financial results and recent corporate developments.
2
2
18
Today, we announced topline results from EMBARK, a double-blind placebo-controlled, Phase 3 clinical study of our gene therapy in patients with Duchenne muscular dystrophy.
4
14
86
Thank you, Assemblyman Hevesi, for your steadfast leadership on this important issue and for making a difference in the lives of Duchenne patients born in New York.
I am extremely proud that my bill
#A5042
was signed into law. This will ensure that all newborns are screened for
#DuchenneMuscularDystrophy
, allowing medical providers to make early detections, mitigate impacts and save lives.
4
6
18
3
2
27
What’s in a gene therapy dose? It depends. How much gene therapy is needed depends on the nature of the disease being treated, and how many and what type of cells are affected. This video takes you inside the science to explore gene therapy and gene therapy dosing. Watch:
2
2
11
